Paul Campanelli named president and CEO of Endo International

Ireland-incorprated drugmaker Endo International (Nasdaq: ENDP) has named Paul Campanelli as president and chief executive, effective immediately.

Mr Campanelli currently serves as president of Endo's Generic and OTC drugs business, Par Pharmaceutical, which accounts for around 60% of Endo's total revenues through the first half of 2016. Mr Campanelli, who will also join Endo's board of directors, succeeds Rajiv De Silva , who has stepped down as president, CEO and a member of the board.

Mr Campanelli, aged 54, joined Endo in 2015 following Endo's acquisition of Par Pharmaceutical, where he had served as CEO since 2012. While CEO of Par, he built a strong leadership team and an industry-leading generics business. Specifically, during his tenure, Par significantly increased total revenue, acquired JHP Pharmaceuticals and established a presence in the European generics market. Since joining Endo, Mr Campanelli has overseen the company's US Generic Pharmaceuticals business.